MedTrace Logo

The Benefits of Continued Use of Ovarian Function Suppression After 5 Years

NCT06050109 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2025-03-17

No results posted yet for this study

Summary

To observe and evaluate the clinical efficacy and safety of continuous use of OFS for premenopausal patients with early breast cancer after 5 years use of OFS.

This study is a multicenter, prospective, observational, non randomized controlled, open-label real world study based on hospital medical record system data, aimed at evaluating the benefits of continuing to use OFS after 5 years of use. The retrospective analysis plan includes patient data from September 1, 2023 to September 1, 2026. Join two cohorts: the continued use group and the discontinued use group after 5 years of OFS, respectively.

Conditions

  • Breast Cancer Female
  • Endocrine Therapy

Interventions

DRUG

OFS continues to use group after 5 years use

Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.

DIAGNOSTIC_TEST

Immunohistochemical detection of HR status

Enrolled patients must be HR-positive premenopausal breast cancer patients

Sponsors & Collaborators

  • Hongmei Zheng, PhD

    lead OTHER

Principal Investigators

  • Hongmei Zheng, Doctor · Study Principal Investigator

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2028-09-01
Completion
2028-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06050109 on ClinicalTrials.gov